NCT00723892View on ClinicalTrials.gov

Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)

CompletedOBSERVATIONAL
Enrollment

614

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Hepatitis C, ChronicHepacivirus
Interventions
BIOLOGICAL

Peginterferon alfa-2b (PegIntron)

Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week

DRUG

Rebetol (Ribavirin)

Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day

BEHAVIORAL

Psychotherapy support program

Each site has implemented a psychotherapy support program.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00723892 - Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) | Biotech Hunter | Biotech Hunter